BIOLOGIC/DISEASE-MODIFYING ANTIRHEUMATIC DRUG (DMARD)
Tremfya is a prescription medication approved by the U.S. Food and Drug Administration (FDA) to treat adults with moderate to severe plaque psoriasis in cases where systemic therapy or phototherapy are warranted. Tremfya may be referred to by its drug name, guselkumab.
Tremfya is an immunomodulator, a drug that modulates the immune system. It is considered a biologic disease-modifying antirheumatic drug (DMARD). Antibodies are proteins used by the immune system to identify and neutralize substances. Tremfya is a genetically engineered antibody believed to work by blocking interleukin-23, a chemical messenger involved in autoimmune attacks. Tremfya prevents interleukin-23 from signaling the immune system to attack the tissues.
How do I take it?
Tremfya is administered as a subcutaneous injection once every eight weeks, after initial loading doses.
The FDA-approved label for Tremfya lists common side effects including upper respiratory infections, headache, injection site reactions, joint pain, diarrhea, stomach flu, ringworm, and herpes simplex infections.
Rare but serious side effects listed for Tremfya can include hypersensitivity reactions, severe infections, and potential birth defects if a woman takes the drug while pregnant.
For more details about this treatment, visit:
Tremfya — Janssen